ASC Modulates CTL Cytotoxicity and Transplant Outcome Independent of the Inflammasome

Cancer Immunol Res. 2020 Aug;8(8):1085-1098. doi: 10.1158/2326-6066.CIR-19-0653. Epub 2020 May 22.

Abstract

The adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD) is known to facilitate caspase-1 activation, which is essential for innate host immunity via the formation of the inflammasome complex, a multiprotein structure responsible for processing IL1β and IL18 into their active moieties. Here, we demonstrated that ASC-deficient CD8+ T cells failed to induce severe graft-versus-host disease (GVHD) and had impaired capacity for graft rejection and graft-versus-leukemia (GVL) activity. These effects were inflammasome independent because GVHD lethality was not altered in recipients of caspase-1/11-deficient T cells. We also demonstrated that ASC deficiency resulted in a decrease in cytolytic function, with a reduction in granzyme B secretion and CD107a expression by CD8+ T cells. Altogether, our findings highlight that ASC represents an attractive therapeutic target for improving outcomes of clinical transplantation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis
  • Bone Marrow Transplantation / adverse effects*
  • CARD Signaling Adaptor Proteins / metabolism*
  • CD8-Positive T-Lymphocytes / immunology*
  • Caspase 1 / metabolism
  • Disease Models, Animal
  • Female
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / immunology*
  • Graft vs Host Disease / metabolism
  • Inflammasomes / immunology*
  • Inflammasomes / metabolism
  • Leukemia / immunology
  • Leukemia / pathology
  • Leukemia / therapy*
  • Mice
  • Mice, Inbred BALB C
  • T-Lymphocytes, Cytotoxic / immunology*

Substances

  • CARD Signaling Adaptor Proteins
  • Inflammasomes
  • Pycard protein, mouse
  • Caspase 1